Skip to main content
Erschienen in: Supportive Care in Cancer 1/2017

17.08.2016 | Original Article

Treating an oft-unrecognized and troublesome entity: using gastric electrical stimulation to reduce symptoms of malignancy-associated gastroparesis

verfasst von: Hamza Shah, Gregg Wendorf, Shifat Ahmed, Lindsay McElmurray, Chris Lahr, Michael Hughes, Brian Beauerle, Ed Miller, Abigail Stocker, Thomas L. Abell

Erschienen in: Supportive Care in Cancer | Ausgabe 1/2017

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Malignancy-associated gastroparesis (MAG) is a cause of morbidity in cancer patients but therapies are lacking. Gastric electrical stimulation (GES) is a novel treatment for MAG. Here, we describe 19 patients with MAG who underwent temporary GES placement.

Patients and methods

Nineteen patients (6 males, 13 females) with various malignancies were reviewed for symptom scores and physiologic measures at baseline and after temporary GES placement. Symptoms were scored by three variables: nausea (N), vomiting (V), and GI total symptom score (TSS). Physiologic profiles were measured by solid and liquid phase gastric emptying scans (GET) at 1, 2, and 4 h and cutaneous electrogastrogram (EGG) and mucosal electrogram (EG) frequencies. Symptoms were measured for 5 days after temporary endoscopic GES placement, and measures were repeated post GES placement.

Results

Baseline GET results displayed delayed gastric emptying in 16 of 19 patients (mean solid retention 21.7 % at 4 h, normal <10 %; mean liquid retention 10.4 % at 4 h, normal <5 %). Cutaneous EGG (mean frequency 5.5 cpm) and EG (mean proximal frequency 5.1 cpm; mean distal frequency 5.1 cpm) showed evidence of neuromuscular dysfunction (normal 2.5–3.3 cpm). Symptom scores in N, V, and TSS showed statistically significant reduction after GES placement.

Conclusion

A small sample of patients with MAG and receiving temporary GES experienced symptom improvement, with less change on gastric emptying time or gastric electrical amplitude or frequency. GES may provide a potential therapeutic option for symptomatic management of MAG and evaluation of these MAG patients after permanent GES placement is ongoing. Prospective studies of MAG using temporary and permanent GES may be warranted.
Literatur
1.
Zurück zum Zitat Shafi MA, Nasser E, Javle MM (2015) Malignancy-associated gastroparesis: pathophysiology and management. In: Savarese D (ed) UpToDate. MA, Waltham Shafi MA, Nasser E, Javle MM (2015) Malignancy-associated gastroparesis: pathophysiology and management. In: Savarese D (ed) UpToDate. MA, Waltham
2.
Zurück zum Zitat Pasricha PJ (2007) The riddle, mystery, and enigma of gastroparesis. J Support Oncol 5:368–370PubMed Pasricha PJ (2007) The riddle, mystery, and enigma of gastroparesis. J Support Oncol 5:368–370PubMed
3.
Zurück zum Zitat Shah H, Kedar A, McElmurray L, et al. (2014) Gastric stimulator, a novel approach in treating malignancy associated gastroparesis. Gastroenterology 146:S695–S696CrossRef Shah H, Kedar A, McElmurray L, et al. (2014) Gastric stimulator, a novel approach in treating malignancy associated gastroparesis. Gastroenterology 146:S695–S696CrossRef
4.
Zurück zum Zitat Donthireddy KR, Ailawadhi S, Nasser E, et al. (2007) Malignant gastroparesis: pathogenesis and management of an underrecognized disorder. J Support Oncol 5:355–363PubMed Donthireddy KR, Ailawadhi S, Nasser E, et al. (2007) Malignant gastroparesis: pathogenesis and management of an underrecognized disorder. J Support Oncol 5:355–363PubMed
5.
Zurück zum Zitat Abell T, McCallum R, Hocking M, et al. (2003) Gastric electrical stimulation for medically refractory gastroparesis. Gastroenterology 125:421–428CrossRefPubMed Abell T, McCallum R, Hocking M, et al. (2003) Gastric electrical stimulation for medically refractory gastroparesis. Gastroenterology 125:421–428CrossRefPubMed
6.
Zurück zum Zitat Wood GJ, Shega JW, Lynch B, et al. (2007) Management of intractable nausea and vomiting in patients at the end of life: “I was feeling nauseous all of the time... nothing was working”. JAMA 298:1196–1207CrossRefPubMed Wood GJ, Shega JW, Lynch B, et al. (2007) Management of intractable nausea and vomiting in patients at the end of life: “I was feeling nauseous all of the time... nothing was working”. JAMA 298:1196–1207CrossRefPubMed
7.
Zurück zum Zitat Camilleri M, Parkman HP, Shafi MA, et al. (2013) Clinical guideline: management of gastroparesis. Am J Gastroenterol 108:18–37 quiz 38CrossRefPubMed Camilleri M, Parkman HP, Shafi MA, et al. (2013) Clinical guideline: management of gastroparesis. Am J Gastroenterol 108:18–37 quiz 38CrossRefPubMed
8.
Zurück zum Zitat Abell TL, Johnson WD, Kedar A, et al. (2011) A double-masked, randomized, placebo-controlled trial of temporary endoscopic mucosal gastric electrical stimulation for gastroparesis. Gastrointest Endosc 74:496–503 e493CrossRefPubMedPubMedCentral Abell TL, Johnson WD, Kedar A, et al. (2011) A double-masked, randomized, placebo-controlled trial of temporary endoscopic mucosal gastric electrical stimulation for gastroparesis. Gastrointest Endosc 74:496–503 e493CrossRefPubMedPubMedCentral
9.
Zurück zum Zitat Tougas G, Eaker EY, Abell TL, et al. (2000) Assessment of gastric emptying using a low fat meal: establishment of international control values. Am J Gastroenterol 95:1456–1462CrossRefPubMed Tougas G, Eaker EY, Abell TL, et al. (2000) Assessment of gastric emptying using a low fat meal: establishment of international control values. Am J Gastroenterol 95:1456–1462CrossRefPubMed
10.
Zurück zum Zitat Guo JP, Maurer AH, Fisher RS, et al. (2001) Extending gastric emptying scintigraphy from two to four hours detects more patients with gastroparesis. Dig Dis Sci 46:24–29CrossRefPubMed Guo JP, Maurer AH, Fisher RS, et al. (2001) Extending gastric emptying scintigraphy from two to four hours detects more patients with gastroparesis. Dig Dis Sci 46:24–29CrossRefPubMed
11.
Zurück zum Zitat Hasler WL (2009) Methods of gastric electrical stimulation and pacing: a review of their benefits and mechanisms of action in gastroparesis and obesity. Neurogastroenterol Motil 21:229–243CrossRefPubMed Hasler WL (2009) Methods of gastric electrical stimulation and pacing: a review of their benefits and mechanisms of action in gastroparesis and obesity. Neurogastroenterol Motil 21:229–243CrossRefPubMed
12.
Zurück zum Zitat Pasricha PJ, Colvin R, Yates K, et al. (2011) Characteristics of patients with chronic unexplained nausea and vomiting and normal gastric emptying. Clin Gastroenterol Hepatol 9(7):567–576 e1-4CrossRefPubMedPubMedCentral Pasricha PJ, Colvin R, Yates K, et al. (2011) Characteristics of patients with chronic unexplained nausea and vomiting and normal gastric emptying. Clin Gastroenterol Hepatol 9(7):567–576 e1-4CrossRefPubMedPubMedCentral
Metadaten
Titel
Treating an oft-unrecognized and troublesome entity: using gastric electrical stimulation to reduce symptoms of malignancy-associated gastroparesis
verfasst von
Hamza Shah
Gregg Wendorf
Shifat Ahmed
Lindsay McElmurray
Chris Lahr
Michael Hughes
Brian Beauerle
Ed Miller
Abigail Stocker
Thomas L. Abell
Publikationsdatum
17.08.2016
Verlag
Springer Berlin Heidelberg
Erschienen in
Supportive Care in Cancer / Ausgabe 1/2017
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-016-3375-z

Weitere Artikel der Ausgabe 1/2017

Supportive Care in Cancer 1/2017 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.